A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
The purpose of this study is to reduce the incidence of grade 2-4 GVHD and WHO grades 3-4 Oral Mucositis.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Palifermin
Phase: Phase 2
Ages Eligible For Study:
- Subjects with hematologic malignancies (including myelodysplastic syndromes [MDS]) who are considered eligible for Cy/TBI +/- VP-16; TBI/VP-16; Mel/TBI; Bu/Cy; Bu/Mel; Flu/Mel conditioning - 18 years of age or older at time of informed consent - Before any study-specific procedure, the appropriate written informed consent must be obtained